The evaluation framework
GLP-1 medications create three distinct types of gastric mucosal stress. Any supplement claiming to protect the stomach during GLP-1 treatment should be evaluated against all three:
Stress 1 — Extended acid and mechanical contact: food and acid remain in contact with the mucosal surface 2–3× longer than normal, requiring a mucosal barrier with adequate buffering capacity.
Stress 2 — Compressed EGFR/ERK repair windows: the inter-meal recovery time for mucosal cell regeneration is reduced, requiring a repair pathway running efficiently — without NF-kB suppression.
Stress 3 — H. pylori extended activity window: in the 62% of symptomatic Indians who carry H. pylori, the bacteria has a longer operational window per meal, driving more NF-kB-mediated inflammation and further suppressing repair.
Antacids
Antacids reduce gastric acid concentration. In the GLP-1 context, this provides partial symptomatic relief by reducing the acidity of gastric contents in extended contact with the mucosal surface. The acid is less acidic — the contact time is unchanged. Antacids do not activate the EGFR/ERK repair pathway, inhibit NF-kB, or address H. pylori inflammation. For patients with significant acid reflux component to their GLP-1 symptoms, antacids are appropriate for short-term relief. As a standalone protective strategy for patients with underlying gastritis, they manage one component of a multi-mechanism problem.
Probiotics
Probiotics are relevant to GLP-1-related bloating from the lower GI mechanism — slowed colonic transit disrupts microbiome balance and increases fermentation-driven gas production. Lactobacillus and Bifidobacterium strains can counteract this disruption. For upper GI side effects — nausea, upper abdominal pain, and the mucosal damage underlying persistent pain — probiotics do not address the relevant mechanisms. Reasonable addition for bloating; not the primary strategy for upper abdominal pain.
PPIs and H2 blockers
When prescribed by a doctor for GLP-1 patients with significant acid-related symptoms, PPIs are appropriate and effective for acid suppression — more comprehensively than antacids. They do not support mucosal repair or address H. pylori inflammation. Long-term PPI use has its own considerations including effects on gut microbiome and nutrient absorption. Outside a doctor's prescription, reaching for PPIs as a self-management strategy for GLP-1 stomach pain is not appropriate.
Flavonoid-based mucosal support
NF-kB inhibition (quercetin): Inhibits the inflammatory transcription factor activated by both H. pylori and by the extended acid exposure GLP-1 creates. Reduces the inflammatory cascade that damages the mucosal surface and suppresses repair.
EGFR/ERK repair activation (glabridin): Directly activates the mucosal cell regeneration pathway that is compressed by GLP-1's shortened inter-meal repair window and suppressed by H. pylori's NF-kB activation.
H. pylori urease inhibition (quercetin + myricetin): Inhibits urease activity, reducing ammonia-mediated mucosal damage from H. pylori during the extended activity window GLP-1 creates.
Summary comparison
Addresses NF-kB inflammation, EGFR/ERK repair deficit, and H. pylori activity — the three mechanisms driving persistent GLP-1 stomach pain beyond the normal adaptation period. Does not interact with GLP-1 receptor mechanisms.
Reduces acid concentration during extended emptying window. Provides partial symptomatic relief for acid-related burning. Does not address repair or inflammation.
Addresses lower GI bloating from fermentation disruption. Does not address upper GI mucosal damage, nausea, or repair.
References
- Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes. Diabetes Care. 2021;44(8):1788–1806. PMID 33526484. GLP-1 gastric emptying mechanism and the three receptor locations responsible for the mucosal stress mechanisms evaluated in this guide.
- Ye YN et al. Licorice flavonoids and gastric mucosal repair via EGFR/ERK pathway. Journal of Ethnopharmacology. 2023;302:115866. PMID 36842733. Glabridin's EGFR/ERK activation mechanism — the basis for TumGard's repair mechanism.
- Crowe SE. Helicobacter pylori infection. New England Journal of Medicine. 2019;380:1158–1165. PMID 30699316. H. pylori NF-kB mechanism and EGFR/ERK suppression — the basis for why H. pylori-positive patients on GLP-1 have compounded mucosal vulnerability.
- Merlin Annie Raj, RD. TumGard India Gut Health Report 2026. Hugg Beverages Pvt. Ltd. 2026. tumgard.com/india-gut-health-report-2026. Source of the 62% H. pylori positivity rate — the India-specific prevalence context for Stress 3 in this guide's evaluation framework.
This guide evaluates supplements against a mechanistic framework. Direct head-to-head clinical trials in GLP-1 patients do not exist for most comparisons. Individual response may vary. Consult your prescribing doctor before adding supplements to GLP-1 treatment.